Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282730 | 0.94 | CRBN (0.55) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL13405486 | 0.92 | CRBN (0.45) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18904220 | 0.91 | CRBN (0.53) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL282762 | 0.90 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24113869 | 0.89 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL283824 | 0.89 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL282665 | 0.89 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL283159 | 0.88 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL282617 | 0.87 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL328502 | 0.87 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10338077-B2 | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins | CELGENE CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170242014-A1 | METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES | CELGENE CORP (US) | 2017-08-24 | — | — | US | disclosed |
| US-9732064-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2428513-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2420498-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9587281-B2 | Cereblon isoforms and their use as biomarkers for therapeutic treatment | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| WO-2017027672-A1 | METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES | CELGENE CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2014179661-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | CELGENE CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140328832-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | CELGENE CORPORATION (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014172436-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140314753-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013106686-A1 | BIOMARKERS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CELGENE CORPORATION (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2009075795-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314753-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, CHEK2, ULK1 | CRBN 1790/4885DDB1 491/4885IKZF3 3439/4885 |
| US-20170242014-A1 | METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES | TSG101, IFNG, IL2 | CRBN 951/4885DDB1 461/4885IKZF3 296/4885 |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | CRBN 1/4885DDB1 1337/4885IKZF3 1569/4885 |
| US-10338077-B2 | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins | CRBN, SERPINA6, UBQLN2 | CRBN 1/4885DDB1 101/4885IKZF3 1806/4885 |
| US-20140328832-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | TP53, TOP2A, BRCA1 | CRBN 475/4885DDB1 59/4885IKZF3 2186/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | CRBN 54/4885DDB1 233/4885IKZF3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.